Glyxambi is a prescription medication that combines two active ingredients—empagliflozin and linagliptin—to effectively manage type 2 diabetes. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps the kidneys remove glucose from the bloodstream, while linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin production in response to meals. This dual-action approach aids in lowering blood sugar levels and reducing the risk of cardiovascular events in individuals with type 2 diabetes and existing heart disease Mayo Clinic.

✅ Key Benefits & Uses

• Blood Sugar Control: Helps lower A1C levels when used alongside diet and exercise.

• Cardiovascular Risk Reduction: Decreases the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease Drugs.com.

• Convenient Dosage: Taken once daily, with or without food, improving patient adherence FDA Access Data.

🧪 How to Use

The recommended dosage is one tablet containing 10 mg of empagliflozin and 5 mg of linagliptin taken once daily in the morning. Depending on individual response and tolerability, the dose may be increased to 25 mg of empagliflozin and 5 mg of linagliptin once daily FDA Access Data. Always follow your healthcare provider’s instructions regarding dosage and administration.

⚠️ Important Safety Information

• Not for Type 1 Diabetes: Glyxambi is not indicated for the treatment of type 1 diabetes mellitus FDA Access Data.

• Renal Function Monitoring: Assess kidney function before initiating treatment and periodically thereafter.

• Risk of Ketoacidosis: Discontinue if signs of ketoacidosis occur, regardless of blood glucose levels FDA Access Data.

• Volume Depletion: Correct any dehydration before starting therapy.

⚠️ Common Side Effects

• Urinary Tract Infections (UTIs): Increased risk due to empagliflozin’s mechanism FDA Access Data.

• Upper Respiratory Tract Infections: Symptoms may include sore throat and nasal congestion.

• Hypoglycemia: Particularly when used with insulin or insulin secretagogues.

• Pancreatitis: Monitor for signs of inflammation of the pancreas Medical News Today.

💡 Why Choose Glyxambi

Glyxambi offers a comprehensive approach to managing type 2 diabetes by combining the benefits of empagliflozin and linagliptin. Its once-daily dosing schedule enhances patient adherence, and its dual mechanism of action provides effective blood sugar control while addressing cardiovascular risks. This makes it a preferred choice for individuals seeking a holistic treatment option Drugs.com.